50
Participants
Start Date
August 11, 2020
Primary Completion Date
January 7, 2025
Study Completion Date
Nivolumab
3mg/kg
Ipilimumab
1mg/kg
NKI-AVL, Amsterdam
The Netherlands Cancer Institute
OTHER